Dossier assessment
Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Linzagolix (uterine fibroids) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Indication:
Adult women of reproductive age with moderate to severe symptoms of uterine fibroids
Result of dossier assessment:
Added benefit not proven
Project details
- Project no.
- A24-92
- Commission
- Commission awarded on 10.09.2024 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Reproductive health and birth
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
- https://doi.org/10.60584/A24-92_en
Connected Projects
-
Dossier assessment
Linzagolix (endometriosis) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed